Nasolina (Oxymetazoline)

Oxymetazoline, the active ingredient in Nasolina, is an alpha‑adrenergic agonist presented as a nasal spray for intranasal use. It provides temporary relief of nasal congestion associated with colds, sinusitis and allergic rhinitis in adults and children over six years of age.

GNH USA supplies Nasolina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and offers reliable global distribution.

Oxymetazoline is used as a topical nasal decongestant to alleviate swelling of the nasal mucosa in several common conditions.

- Common cold: reduces nasal blockage and improves airflow - Sinusitis: alleviates congestion associated with sinus inflammation - Allergic rhinitis: diminishes swelling caused by allergen exposure

Oxymetazoline may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning - Dryness of nasal passages - Sneezing - Headache

Serious or Rare Side Effects: - Rebound congestion with prolonged use - Elevated blood pressure - Rapid heart rate or arrhythmia - Severe nasal ulceration

When using Nasolina, several safety considerations should be observed to minimize risks.

- Duration of use: limit to three consecutive days to avoid rebound congestion - Pregnancy: consult a healthcare professional before use - Breastfeeding: discuss with a physician prior to use - Children under six years: not recommended - Concurrent use with other nasal decongestants: avoid - Store at room temperature: keep in original packaging, protect from moisture and heat

Oxymetazoline can interact with certain medicines, affecting its safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis - Other topical nasal decongestants: additive vasoconstriction leading to severe hypertension

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure lowering - Tricyclic antidepressants and SSRIs: may enhance vasoconstrictive effects - Beta‑blockers: potential for increased cardiovascular effects